MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Press Release
The Myelodysplastic Syndromes Foundation and SparkCures Join Forces to Enhance Clinical Trial Navigation for Myelodysplastic Syndromes Patients

Pittsburgh, PA, September 12, 2023 – The Myelodysplastic Syndromes Foundation (MDS Foundation), a global non-profit advocacy organization dedicated to supporting patients and healthcare providers in the field of myelodysplastic syndromes (MDS) and related diseases, is proud to announce a strategic partnership with SparkCures, LLC, a patient navigation and technology company. This collaboration aims to revolutionize […]

Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes

Efficient, Accurate Risk Stratification Will Transform Patient Care JUNE 12, 2022 YARDVILLE, N.J., June 12, 2022 [Newswire]—Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk stratification upon diagnosis to better inform the way treatment plans are built for patients with Myelodysplastic Syndromes.  “By considering […]

Large International Study Pinpoints Impact of TP53 Mutations on Blood Cancer Severity

Having two mutated copies of the TP53 gene – as opposed to a single mutated copy – is associated with worse outcomes in myelodysplastic syndrome and acute myeloid leukemia. YARDVILLE, N.J., August 25, 2020 ( – The MDS Foundation announces that a large international study led by researchers at Memorial Sloan Kettering finds that having […]

Review answers to commonly asked questions or get answers to your questions from an MDS expert